IL18 and type 2 diabetes mellitus: Similarly, sitagliptin reduced plasma levels of CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1 and E-selectin in 36 subjects with T2D treated for 6 weeks51.